AI-generated summary
The authors report a double-blind randomized trial of 30 patients with diabetic foot ulcers comparing gallium-arsenide laser photobiomodulation with a placebo, both alongside standard wound care. The PBM group had lower serum VEGF and a greater percentage decrease in wound surface area after the intervention, and VEGF was negatively correlated with wound area reduction. The authors describe these findings as suggesting improved angiogenesis.
- Participants
- 30
- Who or what was studied
- Diabetic patients with grade II diabetic foot ulcers
- Wavelengths
- 904 nm
- Limits stated in the abstract
- The abstract reports a small sample of 15 patients per group and does not state any limits beyond its own design.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 904 nm
- Energy density (fluence)
- 2 J/cm2
- Power
- 90 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Diabetic foot ulcer, Angiogenesis, Laser, Randomized controlled trial, Trial registration, Nitric oxide. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.